Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.

by Jian Wang, Agnete Svendsen, Justyna Kmiecik, Heike Immervoll, Kai Ove Skaftnesmo, Jesús Planagumà, Rolf Kåre Reed, Rolf Bjerkvig, Hrvoje Miletic, Per Øyvind Enger, Cecilie Brekke Rygh, Martha Chekenya
Published 2011-01-01

Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.

by Cecilie Brekke Rygh, Jian Wang, Marte Thuen, Andrea Gras Navarro, Else Marie Huuse, Frits Thorsen, Aurelie Poli, Jacques Zimmer, Olav Haraldseth, Stein Atle Lie, Per Øyvind Enger, Martha Chekenya
Published 2014-01-01

Gamma Knife Surgery as Monotherapy with Clinically Relevant Doses Prolongs Survival in a Human GBM Xenograft Model

by Bente Sandvei Skeie, Jian Wang, Ernest Dodoo, Jan Ingeman Heggdal, Janne Grønli, Linda Sleire, Sidsel Bragstad, Jeremy C. Ganz, Martha Chekenya, Sverre Mørk, Paal-Henning Pedersen, Per Øyvind Enger
Published 2013-01-01

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

by Andrea Gras Navarro, Heidi Espedal, Justin Vareecal Joseph, Laura Trachsel-Moncho, Marzieh Bahador, Bjørn Tore Gjertsen, Einar Klæboe Kristoffersen, Anne Simonsen, Hrvoje Miletic, Per Øyvind Enger, Mohummad Aminur Rahman, Martha Chekenya
Published 2019-07-01